|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We used both nested Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) and single step RT-PCR to analyse the FHIT transcripts and found 34 of 39 (87%) tumours and seven of the 11 (64%) corresponding non-cancerous tissues showed low or aberrant expression of FHIT mRNA and the appearance of the aberrant FHIT transcripts depended on the conditions of the RT-PCR.
|
11916557 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
FHIT and WWOX are a tumor suppressor and a candidate suppressor that encompass the FRA3B and FRA16D fragile sites at chromosomes 3p14.2 and 16q23.3-24.1, respectively.
|
15073846 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although the FHIT gene is altered in many human cancers, its status as a tumor suppressor gene has remained controversial, particularly since functional studies provided contradictory results.
|
11313927 |
2001 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We investigated 11 cases of SH by immunohistochemistry, fluorescence in situ hybridization, and polymerase chain reaction-based microsatellite and mutational analyses with particular emphasis on possible alterations of microsatellite loci located at tumor suppressor genes (FHIT, p16, Rb, and p53) involved in lung adenocarcinoma genesis and EGFR, HER2, and K-RAS genes.
|
17895751 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
FHIT transcripts of normal size were observed in 33 out of 34 tumors.
|
9290948 |
1997 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To our knowledge, this is the first report of HDs encompassing the FHIT gene region in primary tumor samples and underscores the usefulness of high resolution genetic analysis of tumor genomes in determining the chromosomal aberrations underlying the malignant progression of CC.
|
9307297 |
1997 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The FHIT gene encompassing the most active common human chromosomal fragile region, FRA3B, was discovered in 1996 and proposed as a tumour suppressor gene for important human cancers.
|
12771912 |
2003 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Because the FHIT gene sustains biallelic intragenic deletions rather than mutations, there has not been evidence that the FHIT gene frequently plays a role in kidney cancer, although replacement of Fhit expression in a Fhit-negative renal carcinoma cell line suppressed tumor growth in nude mice.
|
9679951 |
1998 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
The FHIT gene is inactivated early in the development of many human tumors, and Fhit-deficient mice have increased cancer incidence.
|
12574506 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We conclude that the FHIT gene and other uncharacterized tumour-suppressor genes at 3p14.2 are unlikely to be involved in the pathogenesis of acute leukaemia or progression of CML from chronic phase to blast crisis.
|
9744498 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Genomic DNA was isolated from laser-captured basilar and suprabasilar surface epithelial cells followed by PCR amplification using primer sets that targeted known and presumed tumor suppressor gene loci associated with INK4a/ARF, p53, and FHIT.
|
18413833 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The candidate tumor suppressor gene FHIT has been mapped to 3p14.2, and previous studies have demonstrated reduced or aberrant FHIT transcripts and reduced or absent Fhit protein expression in a large percentage of cervical cancer-derived cell lines and primary cervical carcinomas.
|
10999736 |
2000 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The results of the present study indicate that the FHIT gene is a frequent target in hepatitis C virus-associated HCC and that alterations affecting this gene could be an early event in this type of neoplasm as they were detected in cirrhotic and CAH patients.
|
15610452 |
2005 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
One putative target, 3p14.2, contains the common fragile site, FRA3B, a hereditary renal carcinoma-associated 3;8 translocation and the candidate tumor suppressor gene, FHIT.
|
9063739 |
1997 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Numerous studies have indicated that the FHIT gene on chromosome 3p may play an important role in human neoplasia, although very few studies have investigated the FHIT gene in prostate carcinoma.
|
12627509 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The fragile histidine triad (FHIT) gene is a candidate tumour suppressor gene in breast and other cancers.
|
10930803 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Induction of apoptosis by tumor suppressor FHIT via death receptor signaling pathway in human lung cancer cells.
|
17328863 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The putative tumour suppressor gene FHIT (fragile histidine triad) spans the common fragile site FRA3B, which is highly susceptible to breaks and deletions induced by genotoxic agents.
|
10912665 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Rigorous review of scattered scientific reports on aberrant DNA methylation helped us to select and analyze a potential tumor suppressor gene pair (FHIT and p16 genes) in breast cancer patients.
|
18593338 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo results show that FHIT gene transfer delays tumor growth and prolongs survival in a murine model mimicking human disease.
|
11406559 |
2001 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The majority (4/5) of the patients had LOH at or close to the fragile histidine triad (FHIT) gene (3p14.2; D3S1300), which is a candidate tumor suppressor gene for many cancer types.
|
11115560 |
2001 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
To determine if: (1) 5' CpG island methylation is related to Fhit inactivation; (2) there are tumor or carcinogen-specific methylation patterns, we examined 35 CpG sites in the promoter, exon and intron 1 of the mouse Fhit gene.
|
15007387 |
2004 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We found the epithelial component to be significantly more immunoreactive for cytokeratins, epithelial membrane antigen, carcinoembryonic antigen, cell cycle inhibitors p21Waf1, p27Kip1 and tumor suppressor gene FHIT, whereas the sarcomatoid component, independent of tumor stage and size, was more immunoreactive for vimentin, fascin, and microvascular density.
|
12960804 |
2003 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Two tumor suppressor genes, the fragile histidine triad (FHIT) gene and the WW domain-containing oxidoreductase (WWOX), map to the common fragile sites, FRA3B and FRA16D, respectively.
|
16378185 |
2006 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The fragile histidine triad (FHIT) gene, a putative tumor suppressor gene, overlaps FRA3B.
|
9521167 |
1998 |